Short Interest in Iterum Therapeutics PLC (NASDAQ:ITRM) Rises By 16.7%

Iterum Therapeutics PLC (NASDAQ:ITRM) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 2,045,972 shares, an increase of 16.7% from the February 12th total of 1,752,887 shares. Based on an average daily trading volume, of 839,603 shares, the days-to-cover ratio is currently 2.4 days. Currently, 3.9% of the company’s stock are short sold. Currently, 3.9% of the company’s stock are short sold. Based on an average daily trading volume, of 839,603 shares, the days-to-cover ratio is currently 2.4 days.

Institutional Trading of Iterum Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Iterum Therapeutics during the 3rd quarter valued at about $32,000. Jane Street Group LLC bought a new position in shares of Iterum Therapeutics in the second quarter worth approximately $92,000. OneDigital Investment Advisors LLC increased its stake in shares of Iterum Therapeutics by 18.6% in the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after purchasing an additional 30,000 shares in the last quarter. Alchemi Wealth LLC bought a new stake in shares of Iterum Therapeutics during the 4th quarter valued at $90,000. Finally, Apollon Financial LLC raised its position in shares of Iterum Therapeutics by 151.8% during the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after purchasing an additional 380,000 shares during the period. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Stock Performance

ITRM opened at $0.17 on Tuesday. The firm’s 50 day simple moving average is $0.27 and its two-hundred day simple moving average is $0.46. The company has a market capitalization of $9.11 million, a PE ratio of -0.23 and a beta of 2.96. Iterum Therapeutics has a 1-year low of $0.14 and a 1-year high of $1.50.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ITRM shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. Maxim Group lowered shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Iterum Therapeutics presently has a consensus rating of “Hold” and an average price target of $9.00.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).